ReviewClinical Medicine Insights. Cardiology2015
Low High-Density Lipoprotein and Risk of Myocardial Infarction.
Review in Clinical Medicine Insights. Cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Pooled it
- Association between the Neutrophil-to-HDL-Cholesterol Ratio and Myocardial Infarction: A Cross-Sectional Study.Arquivos brasileiros de cardiologia · 2026Article
- Association between asymmetric dimethylarginine level and central obesity among patients with acute myocardial infarction: exploratory cross-sectional study.BMC cardiovascular disorders · 2026Article
- Association between basal metabolic rate and cardio-metabolic risk factors: Evidence from a Mendelian Randomization study.Heliyon · 2024Article
- Article
- Cardiac biomarkers and detection methods for myocardial infarction.Molecular & cellular toxicology · 2022Review
- The Lipid Paradox is present in ST-elevation but not in non-ST-elevation myocardial infarction patients: Insights from the Singapore Myocardial Infarction Registry.Scientific reports · 2020Observational
- Levels of Blood Biomarkers among Patients with Myocardial Infarction in Comparison to Control Group.Ethiopian journal of health sciences · 2020Article
- Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease.Molecules (Basel, Switzerland) · 2018Review
- Impact of high-density lipoprotein 3 cholesterol subfraction on periprocedural myocardial injury in patients who underwent elective percutaneous coronary intervention.Lipids in health and disease · 2018Observational
- Effect of low and high HDL-C levels on the prognosis of lupus nephritis patients: a prospective cohort study.Lipids in health and disease · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low HDL is an independent risk factor for myocardial infarction. This paper reviews our current understanding of HDL, HDL structure and function, HDL subclasses, the relationship of low HDL with myocardial infarction, HDL targeted therapy, and clinical trials and studies. Furthermore potential new agents, such as alirocumab (praluent) and evolocumab (repatha) are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.